MDMA-Based Combination Treatment Revealed in Clearmind Medicine's Patent Application
Clearmind Medicine has announced the publication of an international patent application for its MDMA-based combination treatment. This advancement is part of the company's collaboration with SciSparc Ltd. (Nasdaq: SPRC), a specialty pharmaceutical company actively engaged in clinical trials.
The unique combination treatment aims to deliver innovative therapeutic options for patients. As research progresses, it holds promise for enhancing treatment outcomes and addressing significant health challenges.
For more details, please visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.